After several months of delays, the U.S. Food and Drug Administration has finally approved the first antidote for Factor Xa anticoagulants, also known as “new generation” blood thinners or “Novel Oral Anti-Coagulants” (NOACs).
As of April 27, all five bellwether trials over the anticoagulant medication Xarelto (rivaroxaban) have ended in outcomes for the defense.
Bayer Scientists Issue Study Contradicting What Their Own Experts Testified to in a Recent Xarelto Trial
Plaintiff lawyers are seeking a new trial in a recent Xarelto trial where the jury ruled in favor of Bayer. Plaintiff lawyers point out that prominent Bayer scientists recently published a medical research study directly contradicting Bayer expert testimony submitted at trial.
As the number of Xarelto lawsuits passes the 11,000 mark and bellwether trials get underway, drugmakers Bayer and Johnson & Johnson have filed a motion in Philadelphia to compel the court to reveal information on whether or not plaintiff cases have been funded by third parties.
Warfarin (a form of rat poison still sold as Coumadin) has been the standard anticoagulant for going on six decades. It is far from a perfect treatment: determining the correct dosage can be difficult, and patients must go on a restricted diet and undergo constant monitoring because of numerous interactions (frequently an issue with elderly patients on numerous prescriptions).
Dr. Robert Califf, President Obama’s nominee to head the Food and Drug Administration, has been the target of serious criticism in recent weeks over his close ties to the pharmaceutical industry. He has received hundreds of thousands of dollars from Big Pharma.
President Obama's recent nominee to head the Food and Drug Administration (FDA) is Robert Califf. Mr. Califf has received huge consulting fees from large pharmaceutical corporations to push their agenda. Worse than that, he played a significant role in the approval of an anti-coagulant medication that is literally killing people.
Rivaroxaban, better known as Xarelto®, has been associated with hundreds of adverse events involving fatal and near-fatal hemorrhaging since it received FDA approval in 2011. Within three years of its arrival on pharmacy shelves, the number of injuries due to Xarelto's side effects has surpassed those caused by rival medication Pradaxa (dabigitran). So far, the number of Xarelto lawsuits has passed the 1,900 mark and is well on its way to 2,000.
Medical malpractice is another common source of litigation. Given the recent news that has come to light over the side effects of Xarelto (rivaroxaban) and the inaccurate dosing information that has led to injury and death, some victims wonder if they have grounds for a medical malpractice suit against their physician and health care provider.
When the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all federal Xarelto lawsuits before a judge in Louisiana, there were approximately fifty cases pending. That was in December 2014. Just over six months later, that number has grown eightfold; currently, there are more than 400 Xarelto lawsuits against Bayer AG and Janssen Pharmaceuticals.